http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112430271-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16621 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2020-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-112430271-B |
titleOfInvention | Bispecific single-chain antibody and application |
abstract | The invention discloses a bispecific single-chain antibody and application thereof, and provides a BiTES-PD-L1 which is a bispecific antibody capable of simultaneously combining CD3 and tumor cell surface PD-L1, and when the BiTES-PD-L1 enters into the body and is combined with T cells, the T cells can be effectively activated, and the T cells are guided to kill the tumor cells. When the BiTEs-PD-L1 is combined with the tumor cells, the tumor cells can be exposed to attract T cells to kill the T cells, and meanwhile, the immunosuppression of PD-1/PD-L1 can be relieved, and the exhaustion of the T cells is delayed. The invention also discloses an oncolytic virus carrying the BiTES-PD-L1 gene, which can specifically proliferate in tumor cells, has the characteristics of high safety and simple preparation process, improves the remaining half-life period of the BiTES-PD-L1 in a body, and shortens the administration frequency and the administration dosage. |
priorityDate | 2020-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 280.